CD274 and colorectal carcinoma: Third, regarding anti-PD-1 or anti-PD-L1 antibody immunotherapy, our results suggest for CRC with wild-type RAS, PD-1/PD-L1 blockage should be combined with anti-VEGF antibodies for right-side disease and with anti-EGFR antibodies for left-side disease.